Introduction {#Sec1}
============

Health-related quality of life (HRQOL) is one of the most important patient-reported outcomes for clinical trials and investigations. In patients with cirrhosis, the role of hepatic encephalopathy (HE), either overt or covert (the former being diagnosed clinically based on the West Haven criteria grade II or higher \[[@CR1]--[@CR3]\], and the latter including grade I according to the West Haven criteria and abnormalities on neuropsychological/neurophysiological testing \[[@CR1]\]), has a major impact on HRQOL. This manuscript only focuses on HRQOL and HE; the impact of therapies on HRQOL change are discussed elsewhere in this supplement.

Effect of Hepatic Encephalopathy (HE) on Health-Related Quality of Life (HRQOL) {#Sec2}
===============================================================================

An impaired HRQOL is a major consequence of HE \[[@CR4]\]. Across the spectrum from covert to overt HE, there have been multiple investigations (Table [1](#Tab1){ref-type="table"}) that have highlighted the multifaceted impairment in this construct across studies and populations \[[@CR1]\]. The tools used to interrogate HRQOL range from the shorter generic Short-Form 36 (SF-36) to the longer generic Sickness Impact Profile (SIP) and the liver-specific Chronic Liver Disease Questionnaire (CLDQ).Table 1Studies prospectively evaluating HRQOL without intervention/medicationStudy, yearInstrument usedPoor QOL compared with patients without HEGroeneweg et al., 1998 \[[@CR36]\]Sickness Impact ProfileYesSchomerus and Hamster, 2001 \[[@CR37]\]Sickness Impact ProfileYesArguedas et al., 2003 \[[@CR4]\]SF-36YesBao et al., 2007 \[[@CR38]\]Chronic Liver Disease Q, SF-36YesZhou et al., 2009 \[[@CR39]\]Chinese adaptation of QOLYesLes et al., 2010 \[[@CR40]\]Chronic Liver Disease Q, SF-36YesBajaj et al., 2011 \[[@CR41]\]PROMIS tools and Sickness\
Impact ProfileYesMoscucci et al., 2011 \[[@CR42]\]SF-36NoParkash et al., 2012 \[[@CR43]\]Chronic Liver Disease QYesLes et al., 2010 \[[@CR40]\]SF-36NoWunsch et al., 2013 \[[@CR44]\]Chronic Liver Disease Q, SF-36NoAhluwalia et al., 2013 \[[@CR45]\]Sickness Impact ProfileYesWang et al., 2013 \[[@CR46]\]Chinese HRQoL instrumentYesNardelli et al., 2013 \[[@CR47]\]SF-36YesThiele et al., 2013 \[[@CR48]\]Chronic Liver Disease QNoMina et al., 2014 \[[@CR49]\]Chronic Liver Disease QYesBarboza et al., 2016 \[[@CR50]\]Specific and general questionnairesYesPaulson et al 2016 \[[@CR51]\]SF-36YesBajaj et al., 2016 \[[@CR52]\]PROMIS toolsYesPatidar et al., 2017 \[[@CR10]\]PROMIS toolsYesLabenz et al., 2018 \[[@CR53]\]Chronic Liver Disease QYes*SF-36* Short-Form 36, *PROMIS* Patient-Reported Outcomes Measurement Information System, *Chronic Liver Disease Q* Chronic liver disease questionnaire, *HRQOL* health-related quality of life, *QOL* quality of life, *HE* hepatic encephalopathy

Most studies performed in HRQOL have used a combination of populations (covert and prior overt HE), as well as a variety of instruments \[[@CR5]\]. The generic instrument most often used is the SF-36, which has a mental and physical component score. This instrument has 36 questions, and, due to the few questions and its generic nature, could underestimate subtle HRQOL changes. As shown in Table [1](#Tab1){ref-type="table"}, studies that have failed to find an impact of HE on HRQOL are those that have used short, non-specific instruments such as the SF-36. On the other hand, studies that have focused on longer generic instruments such as the SIP, or liver-disease specific instruments such as the CLDQ, have mostly found a negative impact of HE on HRQOL. The SIP is a 136-question survey that enquires about health-related issues within 24 h. It has two dimensions (psychological and physical) and 12 domains \[[@CR6]\]. The CLDQ is a 29-question, 5-domain (abdominal symptoms, fatigue, systemic, activity, emotional function and worry) survey that enquires about changes over the last 2 weeks \[[@CR7]\].

In studies of covert HE, where HRQOL changes are subtler than those found in prior overt HE patients, focused liver-specific questionnaires or longer generic questionnaires such as the SIP may be better in finding differences \[[@CR5], [@CR8]\]. HRQOL changes are important in predicting clinically relevant outcomes such as HE recurrence, hospitalizations, and death in outpatients with cirrhosis \[[@CR9], [@CR10]\]. Therefore, patient-reported outcomes pertaining to HRQOL should be considered integral to the prognostication and decision-making process.

Association of HRQOL with Cognitive Impairment {#Sec3}
==============================================

While covert HE is difficult to diagnose, it has multiple negative effects on daily function, progression to overt HE, and survival \[[@CR1]\]. Given the intricate relationship between covert HE and HRQOL, a few studies have used HRQOL questionnaires as a method of diagnosing covert HE \[[@CR5]\]. These strategies are summarized in Table [2](#Tab2){ref-type="table"} \[[@CR11]--[@CR13]\]. This approach is of some practical relevance in the sense that well-being and a good prognosis are the ultimate aims of any diagnostic procedure. However, cognition and HRQOL should be assessed in parallel, and with pertinent tools, just as geriatricians do with cognition and daily living in patients with dementia \[[@CR14]\]. An additional challenge with equating HRQOL with cognitive dysfunction is related to the direct effect of cirrhosis on HRQOL, with HE often reflecting worsening liver function \[[@CR15]\].Table 2Using HRQOL to diagnose covert HEStudy, yearQuestionnaireCovert HE strategyStudy designResultsGroeneweg et al., 2000 \[[@CR13]\]SIP individual questionsEEG, Number Connection Test A and Digit Symbol TestCross-sectional study with 179 outpatients5 questions of the SIP (*I forget a lot, I spend much of the day lying down, I have difficulty doing handwork, I am not working at all, I am confused and start several actions at a time*), sex, Child score and varices were able to diagnose covert HE with 90% sensitivityHirano et al., 2015 \[[@CR12]\]CLDQPaper--pencil testsCross-sectional with regression (*n* = 59) in outpatientsCLDQ Worry domain was an independent factor, with an AUC of 0.71Nabi et al., 2014 \[[@CR11]\]SIP individual questionsPaper--pencil testsCross-sectional and longitudinal study of 170 outpatients over 1 year4 questions of the SIP (*I do not maintain balance, I act irritable or am impatient with myself, I am not doing any of my usual physical recreation or activities, I am eating much less than usual*), age and sex identified covert HE at baseline, 6 months and 12 months with \> 80% sensitivity*HRQOL* health-related quality of life, *HE* hepatic encephalopathy, *EEG* electroencephalogram, *SIP* Sickness Impact Profile, *CLDQ* Chronic Liver Disease Questionnaire

Burden of HE for Patients and Caregivers {#Sec4}
========================================

Unlike most other complications of cirrhosis, HE affects the entire family. Most caregivers of patients with HE are informal in nature, i.e. are not paid and are usually relatives who are mostly not prepared for this burden \[[@CR16], [@CR17]\]. The burden on the patient is characterized by high readmissions, worsening cognitive performance with each HE episode, and a decrease in independence \[[@CR18]--[@CR20]\]. This adds to the burden of HE on these caregivers and on the family, which spans medical, psychosocial, and financial domains \[[@CR21]\]. These changes worsen with the advancing spectrum from covert HE to overt HE, and are also more marked in older cirrhotic patients \[[@CR17]\]. Therefore, the impact of HE and its impairment of daily function and HRQOL is not limited to the patient alone, and the entire family and their resources should be considered.

Sleep Disorders and HE {#Sec5}
======================

So-called sleep--wake inversion, or the combination of restless nights and excessive daytime sleepiness, was first described as a sign of overt HE by Sherlock et al. \[[@CR22]\]. There is also anecdotal evidence that sleep abnormalities worsen following the insertion of transjugular intrahepatic portosystemic shunts \[[@CR23]\], and improve after the initiation of ammonia-lowering treatment \[[@CR24]\]. These findings have led to the idea that the pathogenesis of sleep--wake disturbances in patients with cirrhosis is closely related to that of HE, and that sleep and neuropsychiatric abnormalities are invariably associated in these patients; however, there is limited evidence to support this theory. In particular, both insomnia (i.e. difficulty falling asleep) and fragmented sleep, with multiple night awakenings, have often been reported in patients with cirrhosis and no or limited cognitive abnormalities \[[@CR25], [@CR26]\]. By contrast, there is more convincing evidence of an association between excessive daytime sleepiness and HE. For example, the absence of habitual daytime sleepiness (qualified as present/absent in everyday life) has been shown to have a negative predictive value of 92% in relation to the subsequent occurrence of HE-related hospitalizations over a follow-up period of 8 months \[[@CR27]\]. Even more convincingly, changes in subjective sleepiness have been shown to closely parallel changes in blood ammonia levels in both healthy volunteers and patients with cirrhosis, in studies of hyperammonemia induced by an oral amino acid challenge (i.e. the oral administration of a mixture of amino acids that mimics the composition of blood, and therefore the increase in ammonia levels and the neuropsychiatric changes that are observed after a variceal bleed) \[[@CR28]\]. These observations fit with the hypothesis that HE may be interpreted, at least to some extent, as a syndrome of decreased vigilance \[[@CR29]\]. This interpretation of the syndrome has led to the attempt to combine ammonia-lowering and vigilance-enhancing medication. In a small pilot study, both drugs ([L]{.smallcaps}-ornithine [L]{.smallcaps}-aspartate and caffeine) were shown to contain the increase in ammonia levels/subjective sleepiness and electroencephalographic abnormalities in healthy volunteers, while their effect was less obvious in patients with cirrhosis \[[@CR30]\]. However, the association of ammonia-lowering and vigilance-enhancing medication in the management of HE is worthy of further study.

Cognitive Reserve and Impact on HE and Quality of Life {#Sec6}
======================================================

There are two opposing forces that determine the likelihood of expressing the HE phenotype/developing neuropsychiatric symptoms in the presence of hyperammonemia or in relation to cerebral insults of different types and sizes---cognitive reserve (i.e. the neuroprotection that derives from chronic mental, social, and physical activity) and neuropsychiatric comorbidity. Cognitive reserve represents a resilience factor, while comorbidity increases the likelihood of the phenotype becoming apparent. The first example of how cognitive reserve can modulate the HE phenotype in patients with cirrhosis was provided by Srivastava and colleagues, who described the case of a taxi driver with cirrhosis and significant psychometric impairment whose on-the-road driving test performance remained very good \[[@CR31]\]. Several years later, Montagnese and colleagues reported the cases of two patients with cirrhosis and HE, whose hobby or job were possibly responsible for a selectively enhanced performance in one neuropsychiatric test \[[@CR32]\]. Patel and colleagues subsequently reported better quality of life in patients with cirrhosis and higher cognitive reserve (assessed by a demographically based regression method to estimate pre-morbid intelligence in terms of index scores on the Wechsler Adult Intelligence Scale--Revised), regardless of the presence of covert HE and the degree of hepatic failure \[[@CR33]\]. Finally, Amodio and colleagues \[[@CR34]\] assessed cognitive reserve with a dedicated tool (the Cognitive Reserve Index questionnaire (CRIq) \[[@CR35]\]) in a large group of well-characterized patients with cirrhosis and varying degrees of neuropsychiatric impairment. They reported a correlation between CRIq scores and neuropsychological performance, but not between CRIq and neurophysiological performance, suggesting that cognitive reserve may explain some of the mismatch between neuropsychological and neurophysiological HE indices, and may represent a resilience factor for neuropsychological dysfunction in these patients. While tools to measure cognitive reserve remain sparse, and their validation/use is not yet widespread, clinicians should be alert to the fact that personal inclinations and habits may impinge on neuropsychological performance, in some instances protecting from HE, and, in others, masking its milder phenotypic manifestations.

Conclusions {#Sec7}
===========

There is evidence that HE, even in its milder forms, affects quality of life, sleep--wake patterns, and the balance and relationships between the affected patient and their family. The exact weight of HE over such life domains in relation to the underlying liver failure is not easily established, and the risk and resilience factors of single patients are difficult to measure. Hepatologists and gastroenterologists should become more familiar with the tools and techniques needed to further the understanding within this field of clinical research and clinical practice, which has significant social and economic ramifications.
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